TITLE

EC Forces Aventis To Divest Business

PUB. DATE
August 1999
SOURCE
Chemical Market Reporter;08/16/99, Vol. 256 Issue 7, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Hoechst and Rhone-Poulenc have to license or sell some of their businesses in pharmaceuticals and agrochemicals to gain the European Commission's approval for their merger into Aventis. Plan of the companies for their cobalamines sector; Other plans of the companies.
ACCESSION #
2192375

 

Related Articles

  • Aventis draws praise from analysts. Mirasol, Feliza // Chemical Market Reporter;12/14/98, Vol. 254 Issue 24, p10 

    Highlights analysts' views on Aventis, the life sciences company created by Hoechst AG and Rhone-Poulenc SA. Research and development budget for Aventis; Aventis' need to strengthen its operations to post the high profits of other giant pharmaceutical manufacturers.

  • Drugs giant seeks global agency. Killgren, Lucy // Marketing Week;2/25/1999, Vol. 22 Issue 4, p12 

    Reports that pharmaceutical giant Aventis, formed by the merger of Rhone-Poulenc and Hoechst, is seeking a global advertising agency to create a worldwide campaign to launch its new name. Five agencies Aventis has talked to; Background information on products.

  • Hoechst-RP deal at hand. SCOTT, ALEX // Chemical Week;12/2/1998, Vol. 160 Issue 45, p9 

    Reports on a deal between the Hoechst company and the Rhone-Poulenc (RP) company that would combine their life science businesses. Joint statement issued by the companies; Plans for pesticides activities; Expected total sales of the combined animal health business; Speculation on the Hoechst-RP...

  • Enter Aventis, tech giant. SCOTT, ALEX // Chemical Week;1/6/1999, Vol. 161 Issue 1, p46 

    Focuses on the merger agreement between Rhone Poulenc and Aventis. Significance of the merger; Plan of Aventis to establish a technology council to oversee the research & development integration; Comments from Hoechst board member Horst Waesche.

  • R&D Times Two. Stevens, Tim // Industry Week/IW;05/07/2001, Vol. 250 Issue 7, p49 

    Deals with the integration of research and development (R&D) departments of merging companies. Ways by which merging companies can help their R&D staff through the integration; Benefits of the R&D integration to Aventis, the company formed by the merger between Hoechst AG and Rhone-Poulenc SA;...

  • Carat poised for ...20m Aventis win.  // Marketing Week;7/29/1999, Vol. 22 Issue 26, p12 

    Reveals that Carat is the favorite to win a pitch for the global media account for Aventis, the pharmaceutical company to be formed from the merger of Rhone-Poulenc and Hoechst. Total value of the media account.

  • New Life-Science Giant Aventis To Overhaul R&D. Blau, John // Research Technology Management;Jan/Feb2000, Vol. 43 Issue 1, p4 

    Reports on the creation of Aventis SA, a company created from the merger of Hoechst AG and Rhone-Poulenc SA. Number of employees of the company; Total volume of sales of the company; Projected savings the companies will get from their merger; Goal of the merger.

  • Aventis: New Giant on the Block. Alperowicz, Natasha // Chemical Week;2/17/1999, Vol. 161 Issue 6, p55 

    Provides information on Aventis, a combination of Hoechst's and Rhone-Poulenc's (RP) pharmaceutical, agricultural and veterinary businesses. Views of Igor Landau, president of RP and chairman designate of Aventis Pharma; Idea behind the merger; Total savings from the merger.

  • Aventis SA. Gee, Jack // Industry Week/IW;06/07/99, Vol. 248 Issue 11, p30 

    Presents information on the merger of Hoechst AG and Rhone-Poulenc SA. Details on Aventis SA, the life-sciences company which came out of the merger; Discussion on the plans for Aventis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics